These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS. Takač B; Mihaljević S; Glavaš-Obrovac L; Kibel A; Suver-Stević M; Canecki-Varžić S; Samardžija M; Rajkovac I; Kovač D; Štefanić M Acta Clin Croat; 2020 Mar; 59(1):67-80. PubMed ID: 32724277 [TBL] [Abstract][Full Text] [Related]
28. Investigating intestinal inflammation in DSS-induced model of IBD. Kim JJ; Shajib MS; Manocha MM; Khan WI J Vis Exp; 2012 Feb; (60):. PubMed ID: 22331082 [TBL] [Abstract][Full Text] [Related]
29. Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Li Y; Chen J; Bolinger AA; Chen H; Liu Z; Cong Y; Brasier AR; Pinchuk IV; Tian B; Zhou J Inflamm Bowel Dis; 2021 Nov; 27(Suppl 2):S38-S62. PubMed ID: 34791293 [TBL] [Abstract][Full Text] [Related]
30. Microbiota-inducible Innate Immune, Siderophore Binding Protein Lipocalin 2 is Critical for Intestinal Homeostasis. Singh V; Yeoh BS; Chassaing B; Zhang B; Saha P; Xiao X; Awasthi D; Shashidharamurthy R; Dikshit M; Gewirtz A; Vijay-Kumar M Cell Mol Gastroenterol Hepatol; 2016 Jul; 2(4):482-498.e6. PubMed ID: 27458605 [TBL] [Abstract][Full Text] [Related]
31. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease. Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855 [TBL] [Abstract][Full Text] [Related]
32. Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. Castro AG; Neighbors M; Hurst SD; Zonin F; Silva RA; Murphy E; Liu YJ; O'Garra A J Exp Med; 2000 Nov; 192(10):1529-34. PubMed ID: 11085755 [TBL] [Abstract][Full Text] [Related]
33. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Duchmann R; Schmitt E; Knolle P; Meyer zum Büschenfelde KH; Neurath M Eur J Immunol; 1996 Apr; 26(4):934-8. PubMed ID: 8625991 [TBL] [Abstract][Full Text] [Related]
35. An antibiotic-responsive mouse model of fulminant ulcerative colitis. Kang SS; Bloom SM; Norian LA; Geske MJ; Flavell RA; Stappenbeck TS; Allen PM PLoS Med; 2008 Mar; 5(3):e41. PubMed ID: 18318596 [TBL] [Abstract][Full Text] [Related]
36. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. Hohenberger M; Cardwell LA; Oussedik E; Feldman SR J Dermatolog Treat; 2018 Feb; 29(1):13-18. PubMed ID: 28521565 [TBL] [Abstract][Full Text] [Related]
37. Phenotypic characteristics and clinical manifestations of inflammatory bowel disease in infants and children under 2 years of age in Liaoning Province, China: five of six infants with IL-10R mutations. Teng X; Xu L; Sun M; Guo J Paediatr Int Child Health; 2019 Feb; 39(1):59-64. PubMed ID: 30900524 [TBL] [Abstract][Full Text] [Related]